inhalation spray of amphotericin was initiated. Since airborne aspergillus tends to be seasonal, as is the acquisition of aspergillus and deaths related to the fungus, we elected Aspergillus infections in pediatric bone marrow transplant (BMT) patients are usually fatal. We began the to study the use of nasal amphotericin spray during two aspergillus seasons, to guard against any fluctuation that use of a prophylactic nasal spray of amphotericin in 1990. This nasal spray was provided in addition to lowmight occur from year-to-year and to compare that with the historical control baseline of fatal aspergillus infections in dose intravenous amphotericin. During the time of this study, the number of fatal cases of aspergillus in the our pediatric bone marrow transplant population. We were able to show that over the course of two seasons using pediatric BMT population was reduced significantly from 13.8% to 1.8% (P Ͻ 0.0025) thereby suggesting nasal amphotericin spray, the number of fatal aspergillus infections was significantly reduced. 3, 4 Nasal amphotericin that the use of nasal amphotericin in this population helps to prevent fatal aspergillus infections. The lack spray has now become part of the routine practice in our Pediatric BMT Unit in order to reduce aspergillus infecof significant side-effects and the ease of administration make this a very helpful preventive measure in the tions. supportive care of pediatric bone marrow transplant patients.
All the patients in the treatment group in this study (n = 57) The prolonged immunocompromised status of bone marrow were pediatric patients between the ages of 1.3 and 18.4 transplant patients predisposes to significant fungal infecyears. Fifty-six of the patients underwent an allogeneic tions, particularly aspergillus infections. 1 Aspergillus is a transplant using either a matched sibling donor (five) a parubiquitous fungus which tends to invade sinuses, lungs and tially matched related donor or a closely matched unrelated the brain. Most of the environmental controls in bone mardonor. One patient had an autologous transplant. Eight row transplant units are designed to cleanse the air of asperpatients had non-malignant disease: severe aplastic anemia gillus and other fungal spores and reduce these infections (two), Hurler's disease (three), metochromatic leukodystroin the bone marrow transplant population. 2 phy (one), Sanfilippo type A disease (one) and Fanconi's The majority of patients transplanted in our pediatric unit anemia (one). All the remaining patients either had acute received T lymphocyte-depleted allografts from partially lymphoblastic leukemia, acute nonlymphocytic leukemia, matched related or matched unrelated donors, a circumjuvenile chronic myelogenous leukemia or adult-type stance predisposing to opportunistic infections. Our hospichronic myelogenous leukemia. Patients in this study tal epidemiologists had previously shown that both the received a variety of preparative regimens either consisting adult and pediatric bone marrow transplant programs of VP-16 (varying doses), cytosine arabinoside, cyclophosexperienced seasonal variations in the incidence of asperphamide and total body irradiation (1200 cGy) or busulfan, gillosis in patients at our hospital. During the Junecytosine arabinoside and cyclophosphamide or cyclophosNovember 1988 season and the June-October 1989 season, phamide plus total body irradiation or significantly reduced we had a mortality rate from aspergillosis of 13.8%. With doses of preparative chemotherapy in the case of the child the goal in mind of reducing this figure, we investigated with Fanconi's anemia. No patient was included who other measures to prevent aspergillosis. The use of a nasal previously had a diagnosis of systemic or localized fungal disease.
receiving HEPA-filtered air and hyperchlorinated water. the spray. Others used a metered-dose steroid spray (Beconase AQ; Allen and Hanburys, Research Triangle Children were permitted to leave their rooms and roam the Pediatric BMT Unit hallways, attend school in a classroom Park, NC, USA) just prior to the use of the nasal amphotericin spray, also to reduce the irritation and stinging from on the unit, attend activities everyday in a Child Life room and frequent the kitchen and other lounge areas. Air the nasal amphotericin spray. The nasal amphotericin spray was used until day +180 post-transplant. samples were obtained once per month to culture for fungus and whenever any samples were positive for any fungus, those areas were re-cleaned and not occupied until the air Intravenous amphotericin: All patients received intravenous amphotericin prophylactically at a dose of samples became negative. During the historical period before and during this study, two to three specimens per 0.6 mg/kg twice a week during the first 4 weeks following transplant after which they received one dose of amphoyear are positive for aspergillus, fusarium, or penicillium species. This has not changed from one year to another. No tericin intravenously on a once a week basis until day +180 following the marrow transplant. At least one-half of the laminar air flow rooms were used. Minimal dietary restrictions were in place. Leafy green vegetables and fruits which total use of intravenous and intranasal amphotericin was delivered while the children were outpatients. Patients were could not be peeled were not offered to the patients until their peripheral white blood cell count recovered to greater started on prophylactic antibiotics once their peripheral white blood cell count fell below 1000 cells/mm 3 Chest X-ray infiltrates and evidence of aspergillus in any and Clinics. The intranasally administered amphotericin spray was delivered by a metered-dose atomizing spray culture prompted closer evaluation of the chest and brain usually with CT scans. Sputum was not looked at. Evidence pump. The amphotericin-B injection was added to a sterilized 15 ml plastic reservoir bottle capped with a meteredof systemic spread of fungus had to be documented by one or more of the following: culture, histology or radiodose intranasal pump (Vp7 pump, by Valois of America, Greenwich, CO, USA). The intranasally administered dose graphic visualization. was age dependent. The administered dose was governed by the concentration of amphotericin placed in the reservoir Statistical considerations and the number of actuations per nostril. The age-adjusted dosages are shown in Table 1 .
This study was designed to determine whether mortality due to aspergillus infection in children undergoing marrow The intranasally administered amphotericin spray was begun within the first week of admission to the Pediatric transplantation could be decreased using the proposed treatment and care modifications. We used as our baseline mor-BMT Unit, usually 7-14 days prior to the scheduled bone marrow transplant. A new sterile spray bottle and fresh tality rate the experience with transplant patients during the two previous aspergillus seasons and conducted a study amphotericin was used daily for all inpatients. Outpatients used the same unit for 1 full week before it was replaced. with a single sample of patients. The sample size calculations were based on the following historical information: The tip of the nasal actuator was swabbed with sterile isopropyl alcohol after each dose (ie twice daily). Some patients required the addition of hydrocortisone sodium (1) From June to November 1988, there were 36 pediatric BMT patients at risk for aspergillus infection and five phosphate injection to the nasal amphotericin reservoir bottle in order to reduce nasal stinging and irritation from patients died (13.9%) from aspergillus. Table 1 Amphotericin intranasal spray -dose by age Under 12 months Amphotericin 2.5 mg/ml = 0.25 mg/0.1 ml 1 spray per nostril twice a day = 1 mg/day 12-24 months Amphotericin 5 mg/ml = 0.5 mg/0.1 ml 1 spray per nostril twice a day = 2 mg/day 25 months-5 years old Amphotericin 5 mg/ml = 0.5 mg/0.1 ml 2 sprays per nostril twice a day = 4 mg/day 6-10 years old Amphotericin 5 mg/ml = 0.5 mg/0.1 ml 3 sprays per nostril twice a day = 6 mg/day 11-15 years old Amphotericin 5 mg/ml = 0.5 mg/0.1 ml 4 sprays per nostril twice a day = 8 mg/day Older than 15 years Amphotericin 5 mg/ml = 0.5 mg/0. conduct this study over two 6-month periods during which time the incidence of aspergillus would be at its peak. Since there was such seasonality for aspergillus infections in our hospital pediatric bone marrow transplant population, During the study, from March-November 1990 and from March-November 1991, there were 57 patients at risk. we focused on the 6-month periods from June to November in terms of the potential to reduce the aspergillosis morOnly one fatal case of aspergillus occurred giving a mortality rate of 1.8%. An exact test of the null hypothesis tality. Since the mortality rate did not change during two 6-month periods from 1988 to 1989, the baseline mortality that P = 0.138 vs the alternative hypothesis that P Ͻ 0.138 yields a P-value Ͻ0.0025, which indicates that we would rate from aspergillus was taken to be 13.8%. The null hypothesis was that during the months of June-November be extremely unlikely to observe only one death among 57 patients if the mortality rate were still 13.8%. This suggests 1990 and 1991, the mortality rate from aspergillus infection in children undergoing marrow transplantation would be that the use of nasal amphotericin spray reduced the mortality rate. 13.8%. Since we expected that the proposed modifications in treatment and care could only reduce this rate, the alterDuring the period of this study, it was extremely rare for aspergillus to be proven and then the child survive longnative hypothesis was that the mortality rate would be less than 13.8%. We determined that with a sample size of 54, term. we would have 80% power to detect a decrease from 13.8% to 4% using a significance level of P = 0.05. The number Toxicity of patients available at our institution undergoing such high-risk transplants precluded a randomized study.
We evaluated amphotericin-B absorption following shortterm intranasal amphotericin administration. Twelve of the Therefore, given the past numbers of transplant patients, it was decided that we would conduct this study for 2 years children in this study received 1-5 mg of intranasal amphotericin-B twice daily (0.1-0.3 mg/kg/day) for 4-5 days (June to November of 1990 and 1991) to accumulate enough pediatric BMT patients at risk for aspergillosis.
before concurrent intravenous use. Blood was drawn 2-3 h after intranasal administration, following 1-10 intranasal Given the sample size, we did not plan to accrue enough patients to conduct any stratified analyses to determine amphotericin-B doses. Serial samples were drawn before the first and after the second, fifth and eighth intranasal whether specific patient subgroups were more at risk than others. However, our plan was to answer the basic question amphotericin doses in seven of the 12 children in order to detect serum accumulation. A highly sensitive and specific of whether the risk was significantly reduced from the prestudy level. We conducted a one-sample binomial test to HPLC assay for serum amphotericin was performed (E Bernard, Memorial Sloan-Kettering) on a single batch of determine whether there was a reduction in risk. All surviving patients were followed for at least 3 years after the serum specimens banked frozen at −70°C. Of note was the fact that there was no detectable amphotericin-B in 37 conclusion of the study.
samples drawn when intranasal amphotericin-B was being used alone (ie less than 5 ng/ml). Serum amphotericin-B levels varied from 190-470 ng/ml during periods when Results intravenous amphotericin-B was given. Transnasal systemic amphotericin-B absorption was estimated to be less than During the period of June-November 1988, there were 36 children at risk of developing aspergillus who had under-1-2% of an intravenous amphotericin dose with no evidence of accumulation over the short-term study. No gone transplant. Five died of aspergillus, giving an incidence of 13.9%. During the second period of Decembersystemic toxicity was anticipated with long-term intranasal amphotericin-B due to the lack of any meaningful June 1989, there were 35 children at risk who underwent transplant then with only one patient dying of aspergillus, systemic accumulation. Almost uniformly, patients complained of a stinging sengiving an incidence of 2.9%. As can be seen in Table 2 , a similarly high incidence of aspergillus was seen in the sation in the nasal mucosa upon using the intranasally administered amphotericin spray. Periodically, many June-October 1989 period. We had previously known patients would have nose bleeds secondary to transplantassociated thrombocytopenia necessitating interruption of use a beclomethasone inhaler just prior to the instillation of the intranasally administered amphotericin spray and obtain relief. Otherwise, there were no other toxicities seen with increased number of fungal infections in these types of patients. Thus, it was even more imperative to develop a the use of intranasally administered amphotericin spray.
method to prevent aspergillosis in these patients who remain quite immune suppressed. The majority of children who acquire aspergillosis durDiscussion ing the period when they remain immunocompromised after a marrow transplant will succumb to aspergillosis. The As early as 1984, the use of amphotericin nasal spray for prophylaxis against aspergillosis in neutropenic patients infection is particularly lethal in patients during the first month or two after a marrow transplant. Most bone marrow was reported. 5 This study, like ours, used a historical control and showed that there appeared to be a significant transplant units are constructed to reduce patient exposure to airborne fungal spores and thereby reduce the incidence reduction in the incidence of invasive aspergillosis. 5 In this earlier report, very little information was presented about of fatal aspergillosis.
There have been a number of reports over the past 10 the types of patients who received prophylaxis and the duration of their immune suppression. Unlike bone marrow years on the use of a variety of techniques to prevent systemic fungal infections in marrow transplant patients, using transplant patients who may be quite immune suppressed for more than a year after transplant, particularly due to intravenous or aerosolized amphotericin, itraconazole, fluconazole, or other anti-fungals. [17] [18] [19] [20] The unique aspects of delays of lymphocyte recovery and the prolonged use of medications to prevent graft-versus-host disease, patients our study include the following: receiving conventional dose cancer chemotherapy alone for a malignancy will often have more rapid immune recovery (1) This was an entirely pediatric study carried out in a and thus, will be less likely to develop opportunistic funprogram where patients are not restricted to laminar air gal infections. 6, 7 flow rooms and are given the freedom of roaming an Following that report, there were two reports of a very entire pediatric bone marrow transplant unit with a effective rat model of pulmonary aspergillosis and the use 'clean' HEPA-filtered environment. of an aerosolized amphotericin-B product for prophylaxis (2) The majority of patients transplanted received T and therapy of the resulting aspergillosis. 8, 9 In this model lymphocyte-depleted marrow from partially matched where all of the rats had an aspergillus bronchopneumonia, family members or unrelated donors, a group known a significantly greater number of animals survived a longer to be at higher risk for the development of significant period of time when treated with an aerosolized amphoinfections. tericin-B solution as opposed to not receiving any therapy (3) The use of intranasally administered amphotericin at all. Since that model, there have been a number of other reduced the incidence of fatal aspergillosis in the pedireports on the use of aerosolized amphotericin in at risk atric bone marrow transplant population. The toxicity patients to prevent aspergillus infections. [10] [11] [12] In addition, from the intranasal amphotericin study drug was miniseveral recent reports have evaluated the efficacy of a lowmal and tolerable. No patients had permanently to disdose intravenous amphotericin-B prophylactic regimen and continue the use of nasal amphotericin spray once it these reports appear to document a reduction in systemic had been started. There was no systemic absorption of fungal infections early after transplant and ultimately an the nasally administered amphotericin so that the use improved survival. 13, 14 Thus, the risks of invasive aspergillof amphotericin in this manner did not interfere with osis may be reduced by administering prophylactic regieither the prophylactic or therapeutic use of systemic mens of intravenously and/or aerosolized amphotericin. amphotericin in patients entered on this study. However, the use of these prophylactic regimens, especially when administered intravenously on a daily basis, may damage renal function for those patients who are already Based upon these findings, the use of intranasally administered amphotericin has become a standard practice in our receiving other nephrotoxic medications, such as cyclosporine and aminoglycosides. 15, 16 pediatric BMT program. We administer the nasal and intravenous amphotericin for 6 months post-BMT since our Another recent trial on the use of a liposomal amphotericin-B product given as prophylaxis did not show benefit studies have shown early immune recovery by the 6-month point post-BMT and since in the historical period of study, from treatment with a prophylactic intravenous regimen, although the liposomal amphotericin product appeared to few cases of aspergillus were seen after that point. We have as yet not determined the extent of penetration of the nasbe well tolerated.
12
Our study differed from those previously reported in that ally administered amphotericin particles within the sinuses or the extent of penetration into the pulmonary parenchyma. we had been using systemic amphotericin-B in almost all of the patients beforehand. We added the prophylactic Our impression is that most of the amphotericin spray stays within the nasal mucosa, cutting down on the risk of acquiramphotericin spray to the regimen our patients received. Our study population consisted mostly of those who had ing aspergillus through the respiratory tract. Patients had a high degree of compliance with this medication. However, received T lymphocyte-depleted marrow from either a partially matched family member (DR-identical or completely we hope to determine whether there is a better way to package the amphotericin to reduce the irritation to the nasal haploidentical) or a closely matched unrelated donor. Such transplants have a more prolonged period of immune recovmucosa. In summary, this easily formulated intranasally adminisery and thus a more prolonged period of infection risk. Indeed, we and others have previously documented an tered amphotericin spray helped to reduce the incidence of
